Aptose Biosciences Enhances Executive Compensation and Roles
TipRanksMay 1 16:44 ET
What Makes Aptose Biosciences (APTO) a New Buy Stock
Yahoo FinanceApr 5 12:00 ET
Aptose Biosciences Is Maintained at Overweight by Piper Sandler
Aptose Biosciences Is Maintained at Overweight by Piper Sandler
Dow JonesApr 3 12:09 ET
Express News | Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target
Moomoo 24/7Apr 3 11:58 ET
Aptose Biosciences' Strategic Shift to Front-Line AML Therapy Garners Buy Rating
TipRanksMar 27 17:05 ET
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 27 08:26 ET
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 27 06:32 ET
Express News | HC Wainwright & Co. Maintains Buy on Aptose Biosciences, Maintains $23 Price Target
Moomoo 24/7Mar 27 06:22 ET
Aptose Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 1394.67% HC Wainwright & Co. $23 → $23 Maintains Buy 02/01/2024 224.93% Piper Sandler $12 → $5
BenzingaMar 27 06:21 ET
Earnings Call Summary | Aptose Biosciences(APTO.US) Q4 2023 Earnings Conference
The following is a summary of the Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript:Financial Performance:In 2023, Aptose Biosciences managed to finance its activities through various so
moomoo AIMar 26 21:11 ET · Conference Call
Aptose Biosciences GAAP EPS of -$7.58 Beats by $0.40
Seeking AlphaMar 26 16:50 ET
Aptose Biosciences Expands AML Treatment Trials
TipRanksMar 26 16:38 ET
Aptose Biosciences Up 3% After Hours as Its 2023 Loss Widens on Higher R&D Spending
Aptose Biosciences (APS.TO, APTO) was up 3% in after-hours Nasdaq trading after the company on Tuesday said its annual loss widened in 2023 on higher research and development spending. The company, w
MT NewswiresMar 26 16:26 ET
Express News | Aptose Biosciences Q4 EPS $(1.44) Beats $(1.59) Estimate
Moomoo 24/7Mar 26 16:12 ET
Recap: Aptose Biosciences Q4 Earnings
Aptose Biosciences (NASDAQ:APTO) reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:02 PM.Here's what investors need to know about the announcement.EarningsAptose Biosciences beat estim
BenzingaMar 26 16:10 ET
Aptose Reports FY23 Loss Per Share Of $(7.58) Vs $(6.80) Loss Last Year
Aptose Reports FY23 Loss Per Share Of $(7.58) Vs $(6.80) Loss Last Year
BenzingaMar 26 16:06 ET
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"
04:04 PM EDT, 03/26/2024 (MT Newswires) -- Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials"
MT NewswiresMar 26 16:04 ET
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations With Excellent Safety Profile"
04:04 PM EDT, 03/26/2024 (MT Newswires) -- Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across M
MT NewswiresMar 26 16:04 ET
Aptose Biosciences Brief: Q4 Basic and Diluted Loss per Common Share US$7.58
04:03 PM EDT, 03/26/2024 (MT Newswires) -- Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58
MT NewswiresMar 26 16:03 ET
Press Release: Aptose Reports Results for the Fourth Quarter and Full Year 2023
Aptose Reports Results for the Fourth Quarter and Full Year 2023 -- Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML -- Tuspetinib Continues Broad Activity Acros
Dow JonesMar 26 16:01 ET
No Data
No Data